Samanesadat Hosseini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samanesadat Hosseini has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Mahdavi
Endocrinology and Metabolism Research Center Endocrinology and Metabolism Clinical Sciences Institute Tehran University of Medical Sciences Tehran Iran
2 shared publications - Morteza Mehrdad
Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran
2 shared publications - Abolfazl Mohammadkhani
Chemistry Department, Tarbiat Modares University, Tehran, Iran
1 shared publication - Akbar Heydari
Chemistry Department, Tarbiat Modares University, Tehran, Iran
1 shared publication - Ali Moazzam
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Davood Gheidari
Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran
1 shared publication
Latest Publications
- 23 April 2024
- Published by Royal Society of Chemistry (RSC) in Catalysis Science & Technology
- Vol. 14 (11) , 3086-3097
Synthesis of a new 1,2,3-triazoles scaffold using a heterogeneous multifunctional copper photocatalyst for in vitro investigation via click reaction
Fe 3 O 4 @AlZn–Cu is a photocatalyst for 1,2,3-triazole synthesis with Alzheimer's potential. It is a ligand-free, chemo-selective photo-multifunctional catalyst. This is a sustainable approach to organic synthesis, contributing to a greener world.
- 23 April 2024
- Published by Royal Society of Chemistry (RSC) in Catalysis Science & Technology
- Vol. 14 (11) , 3086-3097
Synthesis of a new 1,2,3-triazoles scaffold using a heterogeneous multifunctional copper photocatalyst for in vitro investigation via click reaction
Fe 3 O 4 @AlZn–Cu is a photocatalyst for 1,2,3-triazole synthesis with Alzheimer's potential. It is a ligand-free, chemo-selective photo-multifunctional catalyst. This is a sustainable approach to organic synthesis, contributing to a greener world.
- 8 February 2023
- Published by Springer Nature in Molecular Diversity
- Vol. 27 (5) , 2345-2352
Ethyl 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate in the smiles rearrangement reaction: straightforward synthesis of amino acid derived quinolin-2(1H)-one enamines
This paper describes the development of 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate compound as a heterocyclic enols containing a Michael acceptor so that it participates in an Ugi-type multicomponent condensation through a Smiles rearrangement in replacement of acid components. The new four-component containing 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate, aldehyde derivatives, amine derivatives and isocyanides process leads readily and efficiently to heterocyclic enamines. This report is an outstanding strategy for the preparation of new biologically structures containing peptidic or pseudo-peptidic with quinolin-2(1H)-one scaffolds. Graphical abstract
- 8 February 2023
- Published by Springer Nature in Molecular Diversity
- Vol. 27 (5) , 2345-2352
Ethyl 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate in the smiles rearrangement reaction: straightforward synthesis of amino acid derived quinolin-2(1H)-one enamines
This paper describes the development of 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate compound as a heterocyclic enols containing a Michael acceptor so that it participates in an Ugi-type multicomponent condensation through a Smiles rearrangement in replacement of acid components. The new four-component containing 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate, aldehyde derivatives, amine derivatives and isocyanides process leads readily and efficiently to heterocyclic enamines. This report is an outstanding strategy for the preparation of new biologically structures containing peptidic or pseudo-peptidic with quinolin-2(1H)-one scaffolds. Graphical abstract
- 18 January 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (4) , e6611
Synthesis of CoFe2O4/BiOI nanocomposite; Its application as an antibacterial agent
The antibacterial properties of CFO/BiOI nanocomposite were investigated in our current study because of their importance in Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus cereus. MIC, MBC, Disk Diffusion, and IC50 tests cefalotin (CF), amoxicillin (AMX), gentamicin (GM), Trimethoprim‐sulphamethoxazole (SXT), and Ceftriaxone (CRO) antibiotics in concentration 30, 10, 10, 25, and 30 were used, respectively. Various techniques such as X‐ray diffraction (XRD), scanning electron microscope (SEM), high‐resolution mapping, and energy dispersive X‐ray spectroscopy (EDAX) have been used to determine the properties of produced nanocomposites. The results showed CFO/BiOI nanocomposite exhibits strong significant biological activity against B. cereus. The results of MBC (minimum bactericidal concentration) and MIC (Minimum Inhibition Concentration) tests for CFO/BiOI nanocomposites on bacteria were examined in the range of 0.12–0.48 and 0.06 to 0.24 mg ml−1, respectively. According to the results,, the minimum IC50 value was determined at a concentration of 0.061 mg ml−1. On the other hand, the most resisting and susceptible bacteria in this method were P. aeruginosa and B. cereus, respectively. These findings are identical to a prior study on antibacterial properties of CoFe2O4 nanoparticles. The MBC endpoint is defined as the lowest concentration, which killed 98% of the bacterial population.
- 18 January 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (4) , e6611
Synthesis of CoFe2O4/BiOI nanocomposite; Its application as an antibacterial agent
The antibacterial properties of CFO/BiOI nanocomposite were investigated in our current study because of their importance in Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus cereus. MIC, MBC, Disk Diffusion, and IC50 tests cefalotin (CF), amoxicillin (AMX), gentamicin (GM), Trimethoprim‐sulphamethoxazole (SXT), and Ceftriaxone (CRO) antibiotics in concentration 30, 10, 10, 25, and 30 were used, respectively. Various techniques such as X‐ray diffraction (XRD), scanning electron microscope (SEM), high‐resolution mapping, and energy dispersive X‐ray spectroscopy (EDAX) have been used to determine the properties of produced nanocomposites. The results showed CFO/BiOI nanocomposite exhibits strong significant biological activity against B. cereus. The results of MBC (minimum bactericidal concentration) and MIC (Minimum Inhibition Concentration) tests for CFO/BiOI nanocomposites on bacteria were examined in the range of 0.12–0.48 and 0.06 to 0.24 mg ml−1, respectively. According to the results,, the minimum IC50 value was determined at a concentration of 0.061 mg ml−1. On the other hand, the most resisting and susceptible bacteria in this method were P. aeruginosa and B. cereus, respectively. These findings are identical to a prior study on antibacterial properties of CoFe2O4 nanoparticles. The MBC endpoint is defined as the lowest concentration, which killed 98% of the bacterial population.